Skip to main content

Month: March 2025

Dimensional Fund Advisors Ltd. : Form 8.3 – ENQUEST PLC – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Dimensional Fund Advisors Ltd. in its capacity as investment advisor and on behalf its affiliates who are also investment advisors (”Dimensional”). Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree EnQuest...

Continue reading

A-Mark Continues Expansion into the Bullion Adjacent Collectible Coin Market by Acquiring Stack’s Bowers Galleries, AMS Holding, LLC, and Pinehurst Coin Exchange, Inc.

EL SEGUNDO, Calif., March 10, 2025 (GLOBE NEWSWIRE) — A-Mark Precious Metals, Inc. (NASDAQ: AMRK) (A-Mark or the Company), a leading fully integrated precious metals platform, announced its continued expansion into the collectible coin market with the following acquisitions:On February 28, 2025, A-Mark completed the previously reported acquisition of Spectrum Group International, Inc. (SGI), the parent of Stack’s Bowers Galleries (SBG), one of the world’s largest rare coin and currency auction houses and a leading wholesale and retail dealer specializing in numismatic and bullion products. SBG generated Total Revenue of $536.4 million and EBITDA of $10.9 million during the fiscal year ended June 30, 2024. On March 9, 2025, A-Mark entered into a definitive agreement to acquire the 90% of AMS Holding, LLC (AMS) not owned by A-Mark....

Continue reading

Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement

YOOV Achieves 59.1% Annual Revenue Growth, Reporting Unaudited Revenue of $45.7 Million with Net Income of $3.4 Million for Calendar Year 2024, Versus Unaudited Revenue of $28.7 Million with Net Loss of $2.4 Million for Calendar Year 2023 Upon Consummation of the Merger, Pending Nasdaq Approval, the New Combined Company is Expected to Trade Under the Nasdaq Symbol “YOOV” FREEHOLD, N.J., March 10, 2025 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has entered into a definitive merger agreement with YOOV Group Holding Limited (“YOOV”), a leading provider of business artificial intelligence (“AI”) automation solutions. Under the agreement, YOOV will merge with and...

Continue reading

Serstech receives an order of 2.1 MSEK from its partner Kaiser

Serstech has today received an order from its partner Kaiser in Singapore. The order consists of SERS consumables. The value of the order is 2.1 MSEK, and it will be delivered and invoiced in Q2 2025. For further information, please contact: Stefan Sandor, CEO, Serstech AB Phone: +46 739 606 067 Email: ss@serstech.com or Thomas Pileby, Chairman of the Board, Serstech AB Phone: +46 702 072 643 Email: tp@serstech.com or visit: www.serstech.com This is information that Serstech AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 13:30 CET on March 10, 2025. Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG). About Serstech Serstech delivers solutions for chemical identification and...

Continue reading

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the results of its Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding the protocol for the planned registrational Phase 3 study of eRapa in familial adenomatous polyposis (“FAP”). The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in...

Continue reading

Cohen & Company Reports Fourth Quarter & Full Year 2024 Financial Results

Board Declares Quarterly Dividend of $0.25 per Share PHILADELPHIA and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) — Cohen & Company Inc. (NYSE American: COHN), a financial services firm specializing in an expanding range of capital markets and asset management services, today reported financial results for its fourth quarter and full year ended December 31, 2024. Summary Operating Results    Three Months Ended   Twelve Months Ended($ in thousands) 12/31/24   9/30/24   12/31/23   12/31/24   12/31/23                   Net trading $ 8,947     $ 8,816     $ 7,809     $ 36,409     $ 30,926  Asset management   2,067       2,147       1,919       9,009       7,337  New issue and advisory   10,075       22,459       18,722       63,422       28,264  Principal transactions and other revenue   (2,548 )     (1,727 )     6,014       (29,242 )     16,454  Total...

Continue reading

NETCLASS TECHNOLOGY INC. Strengthens Market Position in Asia with Strategic Acquisition of Japan-based CreateSolutions Co., Ltd.

SHANGHAI and HONG KONG, March 10, 2025 (GLOBE NEWSWIRE) — NETCLASS TECHNOLOGY INC. (the “Company” or “NETCLASS”), a leading B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, and Singapore, today announced its acquisition of a 51% stake in CreateSolutions Co., Ltd. (“CreateSolutions”), a Tokyo-based software company, by investing JPY 2,550,000 to acquire 255 shares of CreateSolutions. CreateSolutions is a software company specializing in customized, high-efficiency, and sustainable technology solutions. Its services include software development, data analysis, business consulting, corporate innovation training, business process optimization, and innovative product design. The acquisition marks a significant step in NETCLASS’ strategy to expand its market across Asia. It provides the Company with a new...

Continue reading

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung (NSCLC), gastric and esophageal cancer PRT3789 monotherapy dose escalation enrollment is nearing completion and dose escalation in combination with docetaxel continues with plans to present additional results from both cohorts in the second half of 2025 Enrollment into the Phase 1 study of Prelude’s once daily, oral SMARCA2 degrader, PRT7732 is on track and an interim data update is anticipated in the second half of 2025 Current cash runway into second quarter of 2026 with $133.6 million in cash, cash equivalents and marketable securities as of December 31, 2024  WILMINGTON, Del., March 10, 2025 (GLOBE NEWSWIRE) — Prelude Therapeutics...

Continue reading

Applied Materials Increases Quarterly Cash Dividend by 15 Percent and Announces New $10 Billion Share Repurchase Authorization

SANTA CLARA, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that its Board of Directors has approved a 15-percent increase in the quarterly cash dividend, marking eight consecutive years of higher dividends. The increase results in a quarterly dividend of $0.46 per share payable on June 12, 2025 to shareholders of record as of May 22, 2025. The Board also approved a new share repurchase authorization enabling Applied to buy back an additional $10 billion of its shares over time. This supplements the previous authorization which had approximately $7.6 billion remaining at the end of the first quarter of fiscal 2025. “Over the past 10 fiscal years, Applied Materials has distributed nearly 90 percent of free cash flow to shareholders,” said Brice Hill, Senior Vice President and CFO. “The dividend...

Continue reading

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board. These preclinical studies mark a step forward in evaluating Polyrizon’s Trap and Target™ (T&T) platform for the intranasal administration of Naloxone, an opioid...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.